N/A
N=10
Golimumab in Juvenile Idiopathic Arthritis-associated Uveitis Failing Adalimumab
JIA Associated Uveitis
Bottom Line
View on ClinicalTrials.gov: NCT04200833 ↗Enrolled (actual)
10
Serious AEs
0.0%
Results posted
May 2022
Primary outcome: Primary: Number of Participants Reported as Complete Responders to Golimumab — 8 Participants
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- Golimumab (Drug)
- Age
- Pediatric, Adult, Older Adult
- Sex
- All
- Sponsor
- Medical University of Graz
- Primary completion
- Jul 2021
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants Reported as Complete Responders to Golimumab |
8 | — |
| SECONDARY Best Corrected Visual Acuity (BCVA) |
0.27 | — |
| SECONDARY Number of Patients With Ocular Discomfort |
— | — |
| SECONDARY Steroid Sparing Potential |
0.19 | — |
Summary
To asses the use of golimumab, a fully humanized anti-TNF Alpha monoclonal antibody, in juvenile idiopathic Arthritis-associated uveitis refractory to adalimumab.
Eligibility Criteria
Inclusion Criteria
- JIA associated Uveitis
- Treatment failure with adalimumab
Exclusion Criteria
- Uveitis due to other causes
- Adalimumab Initiation because of non ocular reasons
Data sourced from ClinicalTrials.gov (NCT04200833). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.